These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14615659)

  • 1. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.
    O'Brien ME; Clark RA; Besch CL; Myers L; Kissinger P
    J Acquir Immune Defic Syndr; 2003 Dec; 34(4):407-14. PubMed ID: 14615659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.
    Yuan Y; L'italien G; Mukherjee J; Iloeje UH
    HIV Med; 2006 Apr; 7(3):156-62. PubMed ID: 16494629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.
    Silverberg MJ; Gore ME; French AL; Gandhi M; Glesby MJ; Kovacs A; Wilson TE; Young MA; Gange SJ
    Clin Infect Dis; 2004 Sep; 39(5):717-24. PubMed ID: 15356788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
    Sabin CA; Smith CJ; Delpech V; Anderson J; Bansi L; Gilson R; Schwenk A; Leen C; Gazzard B; Porter K; Mackie N; Fisher M; Orkin C; Johnson M; Easterbrook P; Hill T; Phillips AN;
    HIV Med; 2009 Jan; 10(1):35-43. PubMed ID: 19018876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.
    Palladino C; Briz V; Bellón JM; Climent FJ; de Ory SJ; Mellado MJ; Navarro ML; Ramos JT; Taveira N; de José MI; Muñoz-Fernández MÁ;
    PLoS One; 2014; 9(5):e96307. PubMed ID: 24788034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants.
    van Roon EN; Verzijl JM; Juttmann JR; Lenderink AW; Blans MJ; Egberts AC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):290-4. PubMed ID: 10077179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
    Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
    HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study.
    Amera TG; Bogale KA; Tefera YM
    AIDS Res Ther; 2021 Dec; 18(1):93. PubMed ID: 34863200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.
    Lucas GM; Chaisson RE; Moore RD
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):321-8. PubMed ID: 12843742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.